Phocas Financial Corp. Purchases 70,403 Shares of Ralliant Corporation $RAL

Key Points

• Phocas Financial Corp. increased its position in Ralliant by 81.2% in Q4, buying 70,403 shares to own 157,116 shares (about 0.14% of Ralliant) valued at roughly $7.999 million and making Ralliant its 29th-largest holding (~1.0% of Phocas's portfolio).
• Ralliant beat Q4 estimates with $0.69 EPS versus $0.67 expected and $554.6M in revenue versus $543.0M expected, and set Q1 2026 guidance of $0.460–0.520 EPS and FY2026 guidance of $2.220–2.420 EPS.
• Analyst sentiment is mixed but the consensus is a Moderate Buy with an average price target of $50.50; the stock trades at a P/E of 23.74, has a $5.20B market cap, and pays a $0.05 quarterly dividend (0.4% yield).

Phocas Financial Corp. increased its position in Ralliant Corporation (NYSE:RAL - Free Report) by 81.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 157,116 shares of the company's stock after purchasing an additional 70,403 shares during the quarter. Ralliant makes up about 1.0% of Phocas Financial Corp.'s portfolio, making the stock its 29th biggest position. Phocas Financial Corp. owned approximately 0.14% of Ralliant worth $7,999,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of RAL. Cetera Investment Advisers bought a new position in Ralliant in the second quarter worth approximately $700,000. Russell Investments Group Ltd. bought a new position in Ralliant in the second quarter worth approximately $1,465,000. EverSource Wealth Advisors LLC bought a new position in Ralliant in the second quarter worth approximately $39,000. First Trust Advisors LP bought a new position in Ralliant in the second quarter worth approximately $2,013,000. Finally, Federated Hermes Inc. bought a new position in Ralliant in the second quarter worth approximately $326,000.

Ralliant Stock Performance

Shares of RAL stock opened at $46.54 on Wednesday. The firm has a market capitalization of $5.20 billion and a price-to-earnings ratio of 23.74. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. The business has a fifty day moving average of $43.69 and a 200 day moving average of $46.76. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $57.02.

Ralliant (NYSE:RAL - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analysts' expectations of $543.04 million. The company's quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 23rd. Shareholders of record on Monday, March 9th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Ralliant's dividend payout ratio (DPR) is presently 10.20%.

Insider Buying and Selling at Ralliant

In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of Ralliant stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the completion of the transaction, the senior vice president owned 46,756 shares in the company, valued at approximately $2,104,020. This trade represents a 10.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kate Mitchell acquired 2,350 shares of Ralliant stock in a transaction on Tuesday, February 10th. The shares were bought at an average price of $42.48 per share, with a total value of $99,828.00. Following the purchase, the director directly owned 8,411 shares in the company, valued at approximately $357,299.28. The trade was a 38.77% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 8,145 shares of company stock worth $332,233.

Analysts Set New Price Targets

Several brokerages have issued reports on RAL. Barclays dropped their target price on Ralliant from $60.00 to $52.00 and set an "overweight" rating on the stock in a research report on Monday, February 9th. Zacks Research raised Ralliant from a "strong sell" rating to a "hold" rating in a research report on Monday. Weiss Ratings cut Ralliant from a "hold (c)" rating to a "sell (d)" rating in a research report on Thursday, February 5th. Royal Bank Of Canada dropped their target price on Ralliant from $52.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $45.00 target price on shares of Ralliant in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $50.50.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.